Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 1/20 | 0.44 |
| ▸ | CA12 | O43570 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA9 | Q16790 | 1/20 | 0.44 |
| ▸ | HRH2 | P25021 | 1/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.44 |
| ▸ | EGFR | P00533 | 2/20 | 0.43 |
| ▸ | ITK | Q08881 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13738713 | 0.89 | HPGD (0.46) | SCDCA12CA1CA2CA9 | |
| SCHEMBL21049915 | 0.85 | SCD (0.42) | SCDCA12CA1CA2CA9 | |
| SCHEMBL15036786 | 0.79 | CA1 (0.56) | CA12CA1CA2CA9EGFR | |
| SCHEMBL21089840 | 0.78 | CA12 (0.55) | CA12CA1CA2CA9EGFR | |
| SCHEMBL14771916 | 0.78 | KDM4E (0.56) | CA12CA1CA2CA9EGFR | |
| SCHEMBL31627058 | 0.77 | TDP1 (0.44) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL18551719 | 0.76 | CA12 (0.53) | CA12CA1CA2CA9EGFR | |
| SCHEMBL29800785 | 0.76 | TDP1 (0.47) | CA12CA1CA2CA9ALDH1A1 | |
| SCHEMBL3980344 | 0.75 | CA12 (0.52) | CA12CA1CA2CA9EGFR | |
| SCHEMBL17974300 | 0.75 | CA12 (0.54) | CA12CA1CA2CA9EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109689661-B | Macrocyclic inhibitors of myeloperoxidase | 百时美施贵宝公司 | 2021-10-15 | — | — | CN | disclosed |
| US-10577383-B2 | Macrocyclic inhibitors of myeloperoxidase | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-03 | — | — | US | disclosed |
| US-20190177340-A1 | MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE | BRISTOL MYERS SQUIBB CO (US) | 2019-06-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190177340-A1 | MACROCYCLIC INHIBITORS OF MYELOPEROXIDASE | EPX, MPO, SERPINB1 | SCD 1162/4885CA12 3140/4885CA1 2716/4885 |
| US-10577383-B2 | Macrocyclic inhibitors of myeloperoxidase | EPX, MPO, SERPINB1 | SCD 1162/4885CA12 3140/4885CA1 2716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.